Reactive oxygen species and autophagy modulation in non-marine drugs and marine drugs

38Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

It is becoming more understandable that an existing challenge for translational research is the development of pharmaceuticals that appropriately target reactive oxygen species (ROS)-mediated molecular networks in cancer cells. In line with this approach, there is an overwhelmingly increasing list of many non-marine drugs and marine drugs reported to be involved in inhibiting and suppressing cancer progression through ROS-mediated cell death. In this review, we describe the strategy of oxidative stress-based therapy and connect the ROS modulating effect to the regulation of apoptosis and autophagy. Finally, we focus on exploring the function and mechanism of cancer therapy by the autophagy modulators including inhibitors and inducers from non-marine drugs and marine drugs.

Cite

CITATION STYLE

APA

Farooqi, A. A., Fayyaz, S., Hou, M. F., Li, K. T., Tang, J. Y., & Chang, H. W. (2014, November 13). Reactive oxygen species and autophagy modulation in non-marine drugs and marine drugs. Marine Drugs. MDPI AG. https://doi.org/10.3390/md12115408

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free